Tag: medication abortion
New Poll Shows Strong Support in the U.S. for Medication Abortion
Across party lines, Americans support access to medication abortion and the ability to make abortion decisions.
U.S. Supreme Court to Hear Case That Threatens Access to Abortion Medication
Court agrees to review lower court ruling that attempted to reinstate burdensome restrictions on mifepristone.
District Court Ruling in Whole Woman’s Health Alliance v. FDA
On August 21, 2023, a federal court in Virginia denied the Center’s request for a preliminary injunction that would have protected access to the abortion pill mifepristone in Virginia, Montana, and Kansas. In its ruling, the court acknowledged the safety and importance of mifepristone, and the case will proceed in the trial court. Read more about […]
Court Rules to Reinstate Significant Restrictions on Abortion Medication but Not to Revoke FDA Approval of the Drug
Mifepristone will remain available under current regulations due to an earlier U.S. Supreme Court order.
In the Courts: Recent News on U.S. Abortion Rights Cases
Challenging abortion restrictions and bans in state courts.
U.S. Repro Watch, May 17
North Carolina enacts a 12-week abortion ban, hearing on the medication abortion case, harms of abortion bans, and other top news on U.S. reproductive rights.
Center Files Lawsuit to Ensure Access to Abortion Drug in Three States
Lawsuit seeks to protect mifepristone access in Virginia, Montana, and Kansas in light of the drug’s legal uncertainty.
Health, Pharmaceutical and Legal Experts Urge Circuit Court to Reverse Order Attempting to Block FDA’s Approval of Abortion Drug
Case to be argued at the Fifth Circuit Court of Appeals on May 17.
News and Analysis: Alliance for Hippocratic Medicine v. FDA
Read more about the case here: Alliance for Hippocratic Medicine v. FDA
The Center and Movement Partners Urge Court to Block Unprecedented Ruling Rejecting FDA’s Approval of Abortion Drug
Amicus brief of more than 100 reproductive rights, health, and justice partners highlights the proven safety and efficacy of the drug, the ruling’s “immediate and life-threatening consequences,” and the court’s reliance on “debunked data.”
